par Crowley, Andrew A.R.;Natarajan, Harini;Hederman, Andrew A.P.;Bobak, Carly C.A.;Weiner, Joshua J.A.;Wieland-Alter, Wendy;Lee, Jiwon;Bloch, Evan E.M.;Tobian, Aaron A.A.R.;Redd, Andrew A.D.;Blankson, Joel J.N.;Wolf, Dana;Goetghebuer, Tessa ;Marchant, Arnaud ;Connor, Ruth R.I.;Wright, Peter P.J.;Ackerman, Margaret M.E.
Référence eLife, 11
Publication Publié, 2022-03-01
Référence eLife, 11
Publication Publié, 2022-03-01
Article révisé par les pairs
Résumé : | Preexisting antibodies to endemic coronaviruses (CoV) that cross-react with SARS-CoV-2 have the potential to influence the antibody response to COVID-19 vaccination and infection for better or worse. In this observational study of mucosal and systemic humoral immunity in acutely infected, convalescent, and vaccinated subjects, we tested for cross-reactivity against endemic CoV spike (S) protein at subdomain resolution. Elevated responses, particularly to the β-CoV OC43, were observed in all natural infection cohorts tested and were correlated with the response to SARS-CoV-2. The kinetics of this response and isotypes involved suggest that infection boosts preexisting antibody lineages raised against prior endemic CoV exposure that cross-react. While further research is needed to discern whether this recalled response is desirable or detrimental, the boosted antibodies principally targeted the better-conserved S2 subdomain of the viral spike and were not associated with neutralization activity. In contrast, vaccination with a stabilized spike mRNA vaccine did not robustly boost cross-reactive antibodies, suggesting differing antigenicity and immunogenicity. In sum, this study provides evidence that antibodies targeting endemic CoV are robustly boosted in response to SARS-CoV-2 infection but not to vaccination with stabilized S, and that depending on conformation or other factors, the S2 subdomain of the spike protein triggers a rapidly recalled, IgG-dominated response that lacks neutralization activity. |